Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Ocular Therapeutics second quarter 2025 earnings conference call. At this time all participants are in a listen only mode. After the prepared remarks we will conduct a question and answer session. To ask a question please press star 1. As a reminder this conference call is being recorded and will be available for replay on the investor relations section of the Ocular Therapeutics website. I would now like to turn the call over to Ocular's Vice President of Investor Relations, Bill Slattery Jr. Please go ahead Mr. Slattery. Good morning everyone and thank you for joining us today. Earlier this morning we issued a press release and filed our quarterly report on form 10Q, outlining our financial results and business updates for the second quarter of 2025, along with several updates to our registration program for ex-Paxley and wet AMD. Ocular's Executive Chairman, President and CEO, Dr. Praveen Dougal, will summarize recent business highlights before we move to our question and answer session. Joining Dr. Dougal for the Q&A portion of the call will be Donald Notman, Chief Financial Officer and Chief Operating Officer, Sanjay Nayak, Chief Strategy Officer, and Steve Myers, Chief Commercial Officer. We refer everyone to this morning's press release and our form 10Q for a comprehensive update of second quarter 2025 financial and business results. During today's call certain statements we will be making constitute forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially as a result of a variety of risk factors, including risks and uncertainties identified in the risk factor section of our annual report on form 10K and our other SEC filings. With t...